Leigha Senter, MS, LGC, discusses ongoing biomarker research efforts in ovarian cancer.
Leigha Senter, MS, LGC
Advertisement
Articles by Leigha Senter, MS, LGC
Leigha Senter, MS, LGC, discusses optimal testing methods in ovarian cancer.
Leigha Senter, MS, LGC, discusses the development of genetic testing in ovarian cancer.
Leigha Senter, MS, LGC, discusses the implications of identifying genes beyond BRCA1/2 in women with ovarian cancer.
Advertisement
Latest Updated Articles
Potential of Genetic Testing Beyond BRCA1/2 in Ovarian CancerPublished: November 9th 2019 | Updated:
The Development of Genetic Testing in Ovarian CancerPublished: January 7th 2020 | Updated:
Optimal Testing Methods in Ovarian CancerPublished: February 12th 2020 | Updated:
Biomarker Research in Ovarian CancerPublished: February 14th 2020 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Approval Tees Up T-DXd Plus Pertuzumab as a New SOC in HER2+ Breast Cancer
2
NALIRIFOX and FOLFIRINOX Facilitate Personalized Treatment in Metastatic Pancreatic Cancer
3
Iberdomide Plus Daratumumab/Dexamethasone Displays High Response Rates in NDMM
4
FDA Advises on Next Steps for Nogapendekin Alfa Inbakicept Plus BCG sBLA in BCG-Unresponsive Papillary NMIBC
5